Clinical trials: Atypical Lobular Hyperplasia
Atypical Ductal Breast Hyperplasia, Lobular Carcinoma in Situ (LCIS)
Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial
Atypical ductal hyperplasia (ADH) and atypical lobular hyperplasia (ALH) increases breast cancer risk. In post menopausal women, SERMS are standard chemopreventive agents.
- Conditions
- Atypical Ductal Breast Hyperplasia, Lobular Carcinoma in Situ (LCIS), Atypical Lobular Hyperplasia (ALH) of Breast
- Trial name
- NCT01372644
- Testing
- SOM 230 / Pasireotide
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia
Molecular Breast Imaging in Women With Atypia and LCIS
We aim to determine if Molecular Breast Imaging (a new nuclear medicine technique developed at Mayo) can identify malignant breast lesions in women who have atypical ductal hyperplasia, atypical lobular hyperplasia, or lobular…
- Conditions
- Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma in Situ
- Trial name
- NCT00620087
- Testing
- Molecular Breast Imaging, Screening Mammography
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Breast Cancer
FHIR-Enhanced RealRisks to Improve Accuracy of Breast Cancer Risk Assessments
Electronic health records (EHRs) are an increasingly common source for populating risk models, but whether used to populate validated risk assessment models or to de-facto build risk prediction models, EHR data presents several…
- Trial name
- FHIR (NCT05810025)
- Testing
- RealRisks
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Columbia University
Atypical Ductal Breast Hyperplasia, Breast Cancer
A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer
Chemoprevention is the use of certain drugs to keep cancer from forming. The use of atorvastatin (Lipitor) may prevent breast cancer.
- Conditions
- Atypical Ductal Breast Hyperplasia, Breast Cancer, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
- Trial name
- NCT00637481
- Testing
- atorvastatin calcium, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia
Bexarotene in Preventing Breast Cancer in Patients at High Risk for Breast Cancer
This phase I trial studies the side effects and best dose of bexarotene in preventing breast cancer in patients at high risk for breast cancer.
- Conditions
- Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
- Trial name
- NCT03323658
- Testing
- Bexarotene, Questionnaire Administration
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Breast Atypical Hyperplasia, Breast Carcinoma
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
This phase II trial evaluates tamoxifen, with or without omega-3 fatty acids, for reducing risk of breast cancer among postmenopausal and overweight or obese women who are at increased risk of developing breast cancer.
- Conditions
- Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
- Trial name
- NCT06195306
- Testing
- Biospecimen Collection, Mammography, Omega-3-Acid Ethyl Esters
- Where
- 3 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Atypical Hyperplasia of the Breast, Lobular Breast Carcinoma In Situ
Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)
This trial studies the implementation of web-based decision support tools for patients with atypical hyperplasia or lobular carcinoma in situ and healthcare providers.
- Conditions
- Atypical Hyperplasia of the Breast, Lobular Breast Carcinoma In Situ, Pleomorphic Lobular Breast Carcinoma In Situ
- Trial name
- NCT04496739
- Testing
- Cancer Educational Materials, Decision Aid, Interview
- Where
- 97 sites in United States, Guam
- Volunteers
- 412 people, healthy volunteers welcome
- Sponsor
- SWOG Cancer Research Network